



January 26, 2023

BY ELECTRONIC DELIVERY

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
ago.highcostprescriptiondrugs@vermont.gov

Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

Dear Office of the Vermont Attorney General,

TG Therapeutics Inc. ("TG Therapeutics") is issuing this notice pursuant to 18 V.S.A. § 4637(b), which asks prescription drug manufacturers to provide the Office of the Attorney General (the "Office") written notice within three calendar days of releasing in the commercial market a drug with a wholesale acquisition cost ("WAC") that exceeds the threshold set for a specialty drug under the Medicare Part D Program.

On January 26, 2023, TG Therapeutics introduced BRIUMVI™ (ublituximab-xiiy) in the commercial market.¹

NDC	Product Name/Description
73150-0150-06	BRIUMVI™ (ublituximab-xiiy) 150 mg/6 mL Vial

The WAC for the drug product identified above exceeds the threshold set for a specialty drug under the Medicare Part D Program. Please note the WAC-related information provided in this notice may be subject to change.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, TG Therapeutics reserves all of its legal rights. In issuing this notice in a good faith attempt to comply with any requirements under 18 V.S.A. § 4637, TG Therapeutics does not waive any legal claims or legal rights related to potential constitutional defects with Vermont S. 92.

For any questions regarding this notice please contact StateReporting@tgtxinc.com

¹ 18 V.S.A. § 4637 does not currently specify when a manufacturer has a "release of the drug in the commercial market." Further, TG Therapeutics is not aware of any guidance issued by the Office or any Vermont regulations that define "release of the drug in the commercial market" for the purposes of interpreting the requirements under 18 V.S.A. § 4637. TG Therapeutics therefore interprets "the release of the drug in the commercial market," under 18 V.S.A. § 4637, to mean when the date when TG Therapeutics first informs potential customers that a drug is available for order.